Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 4/20 | 0.45 |
| ▸ | KCNK2 | O95069 | 3/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | HNF4A | P41235 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 4/20 | 0.34 |
| ▸ | CNR2 | P34972 | 4/20 | 0.34 |
| ▸ | PTPRZ1 | P23471 | 2/20 | 0.32 |
| ▸ | ABHD12 | Q8N2K0 | 1/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23461032 | 1.00 | CXCR2 (0.45) | CXCR2KCNK2RXRAHNF4ACNR1 | |
| SCHEMBL23460875 | 0.90 | CXCR2 (0.46) | CXCR2CNR1CNR2PTPN1 | |
| SCHEMBL38146973 | 0.90 | CXCR2 (0.46) | CXCR2CNR1CNR2PTPN1 | |
| SCHEMBL23461528 | 0.90 | CXCR2 (0.48) | CXCR2KCNK2RXRAHNF4APTPRZ1 | |
| SCHEMBL23460874 | 0.90 | CXCR2 (0.46) | CXCR2CNR1CNR2PTPN1 | |
| SCHEMBL38146994 | 0.88 | CXCR2 (0.37) | CXCR2CNR1CNR2FFAR4 | |
| SCHEMBL23461460 | 0.88 | CXCR2 (0.37) | CXCR2CNR1CNR2FFAR4 | |
| SCHEMBL23461461 | 0.88 | CXCR2 (0.37) | CXCR2CNR1CNR2FFAR4 | |
| SCHEMBL25548758 | 0.86 | CNR2 (0.35) | CXCR2CNR1CNR2ABHD12FFAR4 | |
| SCHEMBL23461018 | 0.86 | CXCR2 (0.47) | CXCR2CNR1CNR2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630498-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630498-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, CLCN2 | CXCR2 63/4885KCNK2 395/4885RXRA 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.